menu

CME: JAK Inhibition in Rheumatoid Arthritis

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

JAK Inhibition in Rheumatoid Arthritis

JAK Inhibition in Rheumatoid Arthritis
RestartResume
Experts compare data of new and emerging JAK inhibitors in the context of a treat-to-target approach to disease management.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity will provide foundational information for rheumatologists, focusing on changes to recently published guidelines and treatment algorithms that highlight the use of non-tumor necrosis factor (TNF) inhibitors in management strategies for rheumatoid arthritis.

  • Target Audience

    This activity has been designed to meet the educational needs of rheumatologists who care for patients with inflammatory-mediated conditions.

  • Educational Objective

    Upon completion of this activity, participants will be better able to:

    • Aggressively treat RA consistent with updated American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guideline recommendations, including earlier use of non-TNF inhibitor therapy, and with consideration of current and emerging targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs)
  • Faculty

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine and Public Health
    Weill Department of Medicine
    Healthcare Policy and Research
    Weill Medical College of Cornell University
    Adjunct Professor of Law
    Fordham University School of Law
    Attending Rheumatologist
    Hospital for Special Surgery & New York-Presbyterian Hospital
    New York, New York

    Joel Kremer, MD, FACP
    Pfaff Family Professor of Medicine
    Albany Medical College
    Director of Research
    The Center for Rheumatology
    Albany, New York

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Relationship Identified With:

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM

     

    Consultant/Advisor: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Iroko Pharmaceuticals, LLC; Pfizer Inc.
    Speakers Bureau: AbbVie Inc.; Celgene Corporation; Horizon Pharma plc; Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Stocks: AbbVie Inc.; Bristol-Myers Squibb Company; Pfizer Inc.

    Joel Kremer, MD, FACP

    Consultant/Advisor: AbbVie Inc.; Bristol-Myers Squibb Company; Eli Lilly & Company; Gilead Sciences, Inc.; Pfizer, Inc.
    Grants/Research Support: AbbVie Inc.; Eli Lilly & Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation
    Stock Shareholder: Corrona

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

    Lindsay Borvansky: Nothing to disclose
    Andrea Funk: Nothing to disclose
    Liddy Knight: Nothing to disclose
    Jim Kappler, PhD: Nothing to disclose
    Julia Muino: Nothing to disclose

  • Financial Support

    This activity is supported by an independent educational grant from Gilead Sciences, Inc.

  • Provider Information

    Jointly provided by Global Education Group and Integritas Communications.
       

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians. 

    Physician Credit Designation
    Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Nursing Continuing Education
    Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 0.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Fee Information
    There is no fee for this educational activity. 

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Instructions to Receive Credit

    In order to receive credit for this activity, the participant must pass the posttest with a score of at least 70% as well as complete the evaluation. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.